Horizon Pharma Inc: (NASD: HZNP)
$2.37
-0.02 (-0.84%)
Volume 297,166
May 21 03:34 PM ET
Zacks Rank: 4-Sell 
| #4 |
Overview Quote
Stock Activity
| Day Low - High | 2.33 - 2.38 |
| 52wk Low - High | 1.97 - 8.72 |
| Previous Close | 2.39 |
| Avg. Volume | 319,406 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 148.05 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.55 |
| PE (Forward) | 0.00 |
| Current Year Est. | -1.37 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
4 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -1.37 |
| Current Quarter Estimate | -0.31 |
| Most Accurate Estimate | -0.31 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-09-2013 |
| EPS Last Year | -1.80 |
| Expected Earnings Growth | NA |
Company Description
Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company's products include HZT-501 for the treatment of pain, osteoarthritis, and rheumatoid arthritis; LODOTRA for rheumatoid arthritis and asthma; TRUNOC for pain-related diseases and HZN-602 for the treatment of pain and arthritis. Horizon Pharma, Inc. is headquartered in Northbrook, Illinois.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.31 | -0.32 | -1.37 | -0.54 |
| Number of Estimates | 1 | 1 | 2 | 1 |
| Low Estimate | -0.31 | -0.32 | -1.61 | -0.54 |
| High Estimate | -0.31 | -0.32 | -1.12 | NA |
| Year Ago EPS | -0.66 | -0.42 | -2.17 | -1.37 |
| EPS Growth | 53.03% | 23.81% | 37.10% | 60.44% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| HORIZON PHARMA | HZNP | 2.39 | |
|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 14.39 | |
|
| GENTIUM SPA-ADR | GENT | 8.84 | |
|
| AASTROM BIOSCI | ASTM | 0.59 | |
|
| ACHILLION PHARM | ACHN | 7.55 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.27 | |
|
| ALEXION PHARMA | ALXN | 100.03 | |
|
| ALKERMES INC | ALKS | 31.04 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Mixed 3Q for Covidien, Profit Drops
Jul 26, 2012
Earnings Preview: Covidien
Jul 23, 2012
The Zacks Analyst Blog Highlights: Covidien, Horizon Pharma, Johnson and Johnson, CR Bard and Becton, Dickinson
Jun 20, 2012
Covidien Teams Up with Horizon
Jun 19, 2012
Report for HZNP
May 10, 2013
Financials
| EPS TTM | -1.80 |
| Sales | 23 |
| Net Income | -86 |
| Price/Earnings | NA |
| Price/Book | 1.76 |
| Price/Cash Flow | NA |
| Price/Sales | 5.35 |
News
Benzinga Market Primer: Monday, May 13 - Benzinga
May 13, 2013
Horizon Pharma IncCorporate Event Announcement Notice - Wall Street Horizon
May 11, 2013
Benzinga Market Primer: Friday, May 10 - Benzinga
May 10, 2013
Horizon Pharma Announces First Quarter 2013 Financial Results andProvides Business Update - Marketwire
May 10, 2013
Horizon Pharma IncCorporate Event Announcement Notice - Wall Street Horizon
May 10, 2013
Horizon Pharma IncCorporate Event Announcement Notice - Wall Street Horizon
Apr 30, 2013
Horizon Pharma IncCorporate Event Announcement Notice - Wall Street Horizon
Apr 29, 2013
Horizon Pharma to Host Conference Call and Webcast to Discuss FirstQuarter 2013 Financial Results on May 10, 2013 - Marketwire
Apr 29, 2013
Broker Recommendations
| Current ABR | 1.50 |
| ABR (Last Week) | 1.50 |
| # of recs in ABR | 4 |
| Average Target Price | 5.33 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 134 out of 156 |
